Beihai Kangcheng’s Velaglucerase β for Injection is Approved for Marketing in China
May 21, 2025
Source: drugdu
117
Beihai Kangcheng announced that its independently developed injectable velaglucerase beta (Gorinin, CAN103) has been approved for marketing by the China National Medical Products Administration on May 15, 2025 for the treatment of type I and type III Gaucher disease.
Gaucher disease is an autosomal recessive genetic disease caused by a deficiency of glucocerebrosidase, which leads to the accumulation of glucocerebroside in the body and causes a variety of symptoms. Gorenin is the first independently developed long-term enzyme replacement therapy in China suitable for adolescents aged 12 years and above and adults with type I and type III Gaucher disease.
https://finance.eastmoney.com/a/202505203409423342.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- the first of its kind to achieve the primary endpoint of mid-term analysis in nasopharyngeal carcinoma stage III clinical trials with iza bene July 4, 2025
- Gout treatment welcomes new choices! Changchun High tech’s first domestically approved injection of Fuxinqibai monoclonal antibody for market launch July 4, 2025
- this is the path to carbon neutrality July 4, 2025
- Dizal (Jiangsu) Pharmaceutical Co., Ltd. Voluntary Disclosure of Announcement Regarding Accelerated Marketing Approval of Suvoderm® by the U.S. FDA July 4, 2025
- Rare, Recurrent, and Still a Challenge July 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
